ArticleCureus2025
Acute Drug-Induced Hepatitis Associated With Vortioxetine: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is an uncommon but potentially serious adverse reaction that can arise from the use of various antidepressants. Vortioxetine, widely used for the treatment of major depressive disorder due to its favorable efficacy and tolerability profile, has been infrequently associated with hepatic toxicity. We describe the case of a 59-year-old female who developed acute hepatitis with cholestatic features after long-term vortioxetine therapy. Extensive evaluation ruled out viral, autoimmune, and metabolic causes. Liver function improved after the discontinuation of the drug but worsened upon rechallenge, necessitating permanent withdrawal of the drug. A subsequent episode of hepatic failure after exposure to venlafaxine suggested a class-related susceptibility to selective serotonin reuptake inhibitor (SSRI)-induced hepatotoxicity. The patient recovered following cessation of antidepressants and treatment with N-acetylcysteine. This report underscores the importance of considering DILI in patients treated with vortioxetine or other serotonergic antidepressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.